Skip to content
Subscriber Only

Large-Cap Biotech Stocks Will Just Tread Water as Sector Sizzles

  • Drug pricing expected to remain overhang ahead of elections
  • Few catalysts ahead for sector after Biogen’s Alzheimer’s data
Video player cover image
'All Hail the Dollar,' Says Bell Curve Capital's Gersch
Updated on

Investors betting on a resurgence for large-cap biotech stocks shouldn’t hold their breath.

That’s the advice from analysts covering the sector as shares of companies such as Celgene Corp. and Regeneron Pharmaceuticals Inc. have failed to keep pace with their smaller rivals over the past six months. Even as the Nasdaq Biotech Index rose for a seventh straight day on Monday, its longest streak since March, analysts don’t expect the largest names in the group will see a sustained rebound in the second half of the year.